About this trial
Pigmented villonodular synovitis (PVNS) is a rare joint disease caused by the proliferation of synovial tissue, leading to significant pain and joint destruction. It typically begins between the ages of 30 and 50 and significantly affects patients' functionality. The proliferation is due to somatic mutations in some fibroblastic cells within the tissue, which triggers a massive recruitment of inflammatory cells. The condition is considered a benign tumor of the synovial membrane with a major inflammatory component. Diagnosing PVNS requires synovial tissue analysis, obtained either through surgical excision or guided needle biopsy. This biopsy technique, done as an outpatient procedure, is well tolerated and helps confirm the diagnosis before treatment. Our goal is to better understand this disease and determine if the analysis of synovial tissue could serve as a useful biomarker for patient management in the context of personalized medicine.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patient >18 years
Diagnosis of localized or diffuse villonodular synovitis
Referred for therapeutic management
Affiliated with or benefiting from a social security scheme
Disqualifiers
Pregnant women
Nursing mothers
Protected patients: patients under guardianship or curatorship, safeguard of justice
Patients deprived of liberty
Trial design
Single group
Treatments tested in this trial
synovial biopsy
Procedure/SurgerySynovial samples are taken either : * immediately after surgery * during an ultrasound-guided synovial biopsy
Treatment groups
Trial outcomes
Primary outcomes
number of samples
Secondary outcomes
Tissue quality
assessed using Krenn's histological score
number of adverse events
Patient acceptability
using a visual analogue scale
Cluster analysis of results from high-throughput experiments
Sponsors and contacts
Click on the lead sponsor to view all of their trials.